Pulsatile Caffeine Formulation via pH-Sensitive Polymers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nootropic agents lack time-controlled pulsatile release kinetics, making it difficult to achieve precise and adjustable vitalization or sedation, particularly in situations like waking up or managing circadian rhythms.
Innovation Solution
A pulsatile release formulation comprising a nootropic agent and a release-controlling polymeric system, specifically using copolymers of methacrylic acid and methyl methacrylate, or ethyl acrylate, methyl methacrylate, and trimethylammonioethyl methacrylate chloride, to control the release of substances like caffeine, ensuring a lag time before rapid release in the gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If instantaneous release formulation is used, then the absorption process starts immediately, but it cannot achieve time-controlled pulsatile release for vitalization during sleep
Solution Approach 1:
The patent changes the chemical parameter of the polymeric coating system by using copolymers of methacrylic acid and methyl methacrylate with specific molar ratios (1:2.5 to 1:1.5 and 1:1.4 to 1:0.5). These polymers exhibit pH-dependent solubility characteristics that change with gastrointestinal tract conditions, enabling time-controlled release without complex mechanical structures
Solution Approach 2:
The formulation uses a composite polymeric system combining multiple copolymers in specific weight/weight ratios ((a) and (b) at 2 to 6, and (c) and (b) at 0.5 to 2). This composite approach creates a synergistic effect where the different polymers work together to provide the desired pulsatile release profile with a lag time followed by rapid release
2Reliability
If stimulant is administered before sleep, then it can provide wake-up effect, but it causes immediate release and absorption instead of delayed release during sleep
Solution Approach 1:
The formulation is administered before sleep when the patient is still awake, allowing the polymeric coating to remain intact during the sleep period. The coating prevents premature release, and the active ingredient is released automatically when gastrointestinal conditions change, providing reliable wake-up effect without requiring the patient to time the administration precisely
Solution Approach 2:
The pH-sensitive polymeric coating acts as an intermediary barrier that protects the active ingredient from premature release. This coating mediates between the administered drug and the gastrointestinal environment, releasing the drug only when exposed to the specific pH conditions of the distal gastrointestinal tract
3Ease of operation
If alarm clock is used to wake up, then it provides external stimulation, but it tears the person from deep sleep phase causing restlessness and exhaustion
Solution Approach 1:
The active ingredient is released just before the desired wake-up time rather than during or after awakening. This preliminary action allows the drug to be absorbed and take effect during the transition from sleep to wakefulness, reducing sleep inertia and exhaustion by avoiding abrupt interruption of deep sleep
Solution Approach 2:
The patent replaces the mechanical alarm clock system with a chemically-controlled release system. Instead of using external acoustic or sensory signals to force awakening, the formulation uses pH-dependent polymeric chemistry to automatically release the active ingredient at the appropriate time, allowing the body's natural wake-up processes to occur without abrupt disruption
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides a controlled release of nootropic agents, reducing sleep inertia and improving wake-up quality by releasing the active ingredient just before waking, enhancing mental performance and reducing morning depression symptoms.
Implementation Method 1
the release controlling polymeric system comprises: (a) a copolymer of methacrylic acid and methyl methacrylate in a molar ratio of 1:2.5 to 1:1.5; (b) a copolymer of methacrylic acid and methyl methacrylate in a molar ratio of 1:1.4 to 1:0.5
Data Source
AI summary
The present invention relates to a pulsatile release formulation comprising a nootropic agent and a release controlling polymeric system, as well as its therapeutic and non-therapeutic uses. The instant formulations are particularly useful in the therapy of morning depression and/or wake-up difficulties in Delayed Sleep Phase Syndrome, Seasonal Affective Disorders, Narcolepsy, Sleep Deprivation, Major Depression, Idiopathic Insomnia, or Sedative-induced Hang-overs.